With the amount of negative levitra sale attention lately surrounding relationships between physicians and industry, some doctors have had enough. In response to the recent criticisms, Bradley P. Knight, MD, FACC, FHRS, Editor-in-Chief of the Electrophysiology Lab Digest, wrote an article defending the “Legitimate Relationships Between Physicians and Industry.”
January 7, 2011– The United States Supreme Court today will hear First Amendment appeal to Vermont’s Rx data use ban.
Earlier First Circuit federal appeals court decision set up the Supreme Court appeal.
Late last year, the 2nd Circuit Court invalidated the Vermont version of the Rx data restriction law, finding it a violation of the First Amendment. This 2nd Circuit decision is contrary to a 1st Circuit Court decision on similar facts, setting up the US Supreme Court appeal granted today. Although a victory in the Supreme Court is not assured, the Supreme Court has fiercely protected commercial speech in virtually nearly every case before it since the “Central Hudson” test was announced by the Court in the 1970′s.
From Manhattan Institute:
An active partnership between science and commerce underlies Americans’ high standard of living, including their state of cheap viagra online health and the medical discoveries and treatments that have steadily improved it. But a mounting wariness toward collaborations between employees of research institutions and public agencies and those working for pharmaceutical companies and the like, as expressed in increasingly broad conflict-of-interest rules and prohibitions, threatens to disrupt what has been a wide-ranging and productive exchange of knowledge and information.
NEW YORK – (BUSINESS WIRE) – According to Prevention Magazine’s 13th annual national survey Consumer Reaction to DTC Advertising of Prescription Drugs, consumers are paying attention to the FDA regulated “fair balance” mandate between risk and benefit information on all DTC ads; the majority believe pharmaceutical advertising in magazines and television is presented “both fair and balanced.”
Please don”t hold the Mayo
One of the more interesting subtexts surrounding King James” move to Miami is the negative economic impact it will have on the economy of Cleveland specifically and Ohio in general.
A similar subtext (albeit one that has been entirely ignored) is the negative economic impact the State of Michigan will experience following the University of Michigan”s recent announcement that it will ban any industry-sponsored CME.
The following was written by Peter Pitts, blogger at . Comments are encouraged.
Once more into the abyss.
The Accreditation Council for Continuing Medical Education (ACCME), the national body that accredits medical education courses, has decided that physicians and researchers who work inside the pharmaceutical industry will not be allowed to make medical education presentations at medical meetings.
Thanks to Tom Sullivan for providing this roundup of information on current issues that affect the healthcare communication industry. For more of Tom”s commentary and analysis, visit his blog at www.policymed.com
A study by the Cleveland Clinic’s Center for Continuing Education showed that there was no correlation between the perception of bias and the commercial support status of an activity such as continuing medical education.
Comments are welcome here.flagyl generic walmart
The Coalition and Med Ad News are collaborating on a series of podcasts by John Kamp, Coalition Executive Director, on topics vital to the healthcare communication industry. The 4th podcast, “Approach with Caution,” is now available for download. In this segment, Mr. Kamp talks about social media, why legal departments will continue to voice strong resistance to going too far and he also acknowledges the great opportunity social media hold in improving the industry relationship and reputation with consumers.
All 4 podcasts can be downloaded here: prednisone for sale
On June 21, 2007, U.S. Representative Pete Stark introduced a bill titled the “Fair Balance Prescription Drug Advertisement Act of 2007.” H.R. 2823 (110th Cong., 1st Sess.). If enacted, the bill would deny a tax deduction for any expenses associated with a direct-to-consumer (“DTC”) advertisement for a new prescription drug for the first 2 years after approval.